The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
The Plasminogen (Fibrinolytic) System
Abstract
Introduction: The plasminogen (fibrinolytic) system (Fig. 1) comprises an inactive proenzyme, plasminogen, that can be converted to the active enzyme, plasmin. Plasmin degrades fibrin and activates matrix metalloproteinases (MMPs) that, in turn, degrade the extracellular matrix (ECM).1-3 Two physiological plasminogen activators (PAs) have been identified: tissue-type PA (t-PA) and urokinase-type PA (u-PA), which binds to a cellular u-PA receptor (u-PAR). Inhibition of the plasminogen/MMP system occurs at the level of the PA, by specific PA inhibitors (PAIs), at the level of plasmin, primarily by α2-antiplasmin, or at the level of MMPs, by tissue inhibitors of MMPs (TIMPs). The dual roles of the plasminogen system are presently well established. The t-PA-mediated pathway is primarily involved in fibrin homeostasis, and the u-PA-mediated pathway is primarily involved in phenomena, such as cell migration and tissue remodeling. Consequently, the terminology “fibrinolytic system” has become inadequate and, therefore, will be replaced by “plasminogen system” in the present review. In 1980, the state of knowledge concerning the plasminogen system was summarized.4 At that time, most of the components of the system (except the PAIs) were identified and biochemically characterized (except t-PA), but thrombolytic therapy was still in its infancy. The pathophysiologic role of the plasminogen system was deduced indirectly from correlations between levels of its components and clinical disease states, whereas its role in vascular biology, matrix remodeling, tumor growth and dissemination, wound healing, and infection was largely unknown. The last 20 years have witnessed a rapidly progressing elucidation of the biochemistry, (patho)physiology, and therapeutic applications of the plasminogen system. This development has been catalyzed by the emergence of powerful molecular biological technologies, including recombinant DNA techniques for the expression of heterologous proteins and targeted gene manipulation in vivo for the elucidation of the (patho)physiological role of their translation products. The aim of the present review is to summarize the main developments in the plasminogen field since the 1980s. This account will be incomplete, since references to much significant work were omitted due to space limitations. To alleviate this shortcoming, reference is made primarily to review articles, in which more details and citations to original work can be found.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309023291001 · Cited by 4,055
(1993) · New England Journal of Medicine · doi:10.1056/nejm199311253292204 · Cited by 1,866
On the Regulation and Control of Fibrinolysis: Edward Kowalski Memorial Lecture
Collen, D. (1980) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1650023 · Cited by 1,135
Self-citationProteolytic remodeling of extracellular matrix
Birkedal-Hansen, H. (1995) · Current Opinion in Cell Biology · doi:10.1016/0955-0674(95)80116-2 · Cited by 1,074
Basic and clinical aspects of fibrinolysis and thrombolysis
Collen, D., & Lijnen, H. (1991) · Blood · doi:10.1182/blood.v78.12.3114.3114 · Cited by 688
Self-citationAbsence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization
Bajou, K., Noël, A., Gerard, R. D., Masson, V., Brunner, N., Holst-Hansen, C., Skobe, M., Fusenig, N. E., Carmeliet, P., Collen, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0898-923 · Cited by 677
Self-citationUrokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation
Carmeliet, P., Moons, L., Lijnen, R., Baes, M., Lemaître, V., Tipping, P., Drew, A., Eeckhout, Y., Shapiro, S., Lupu, F., et al. (1997) · Nature Genetics · doi:10.1038/ng1297-439 · Cited by 661
Self-citationLoss of Fibrinogen Rescues Mice from the Pleiotropic Effects of Plasminogen Deficiency
Bugge, T. H., Kombrinck, K. W., Flick, M. J., Daugherty, C. C., Danton, M. J. S., & Degen, J. L. (1996) · Cell · doi:10.1016/s0092-8674(00)81390-2 · Cited by 424
Coleman, J. L., Gebbia, J. A., Piesman, J., Degen, J. L., Bugge, T. H., & Benach, J. L. (1997) · Cell · doi:10.1016/s0092-8674(00)80298-6 · Cited by 341
Aspirin, Heparin, and Fibrinolytic Therapy in Suspected Acute Myocardial Infarction
Collins, R., Peto, R., Baigent, C., & Sleight, P. (1997) · New England Journal of Medicine · doi:10.1056/nejm199703203361207 · Cited by 297
Cited by
uPAR: a versatile signalling orchestrator
Blasi, F., & Carmeliet, P. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm977 · Cited by 1,223
Role of the Matrix Metalloproteinase and Plasminogen Activator–Plasmin Systems in Angiogenesis
Pepper, M. S. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq0701.093685 · Cited by 777
Cross Talk Pathways Between Coagulation and Inflammation
Foley, J. H., & Conway, E. M. (2016) · Circulation Research · doi:10.1161/circresaha.116.306853 · Cited by 589
Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease
Lane, D. A., & Grant, P. J. (2000) · Blood · doi:10.1182/blood.v95.5.1517.005k48_1517_1532 · Cited by 495
Molecular Mediators of Angiogenesis
Ucuzian, A. A., Gassman, A. A., East, A. T., & Greisler, H. P. (2010) · Journal of Burn Care & Research · doi:10.1097/bcr.0b013e3181c7ed82 · Cited by 446
Metadata
- Authors
- Collen, D.
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 1999
- Volume
- 82
- Issue
- 08
- Pages
- 259-270
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W1950882931
- Cited by
- 430
- References
- 23
- FWCI
- 9.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Plasminogen (Fibrinolytic) System. https://app.cochat.ai/papers/10.1055/s-0037-1615841
- The paper
- Collen, D. (1999). The Plasminogen (Fibrinolytic) System. Thrombosis and Haemostasis. https://doi.org/10.1055/s-0037-1615841
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.